In conclusion, AML patients with IDH2 R140 mutations tend to achieve more rapid and complete blast cytoreduction following intensive induction compared with IDH2 R172, while IDH1‐mutated patients showed comparable outcomes to the IDH2 group overall. Here, IDH2 is linked to acute myeloid leukemia.